Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares Outstanding
Ratios

Outlook Therapeutics (OTLK) Accumulated Depreciation & Amortization (2016 - 2020)

Historic Accumulated Depreciation & Amortization for Outlook Therapeutics (OTLK) over the last 6 years, with Q2 2020 value amounting to $50959.0.

  • Outlook Therapeutics' Accumulated Depreciation & Amortization fell 9388.53% to $50959.0 in Q2 2020 from the same period last year, while for Jun 2020 it was $50959.0, marking a year-over-year decrease of 9388.53%. This contributed to the annual value of $3.4 million for FY2019, which is 1006.83% up from last year.
  • Outlook Therapeutics' Accumulated Depreciation & Amortization amounted to $50959.0 in Q2 2020, which was down 9388.53% from $63775.0 recorded in Q1 2020.
  • Over the past 5 years, Outlook Therapeutics' Accumulated Depreciation & Amortization peaked at $3.4 million during Q3 2019, and registered a low of $50959.0 during Q2 2020.
  • Over the past 5 years, Outlook Therapeutics' median Accumulated Depreciation & Amortization value was $693206.5 (recorded in 2017), while the average stood at $1.1 million.
  • In the last 5 years, Outlook Therapeutics' Accumulated Depreciation & Amortization skyrocketed by 17310.86% in 2016 and then crashed by 9388.53% in 2020.
  • Outlook Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $669780.0 in 2016, then rose by 1.02% to $676624.0 in 2017, then grew by 21.64% to $823077.0 in 2018, then plummeted by 92.25% to $63776.0 in 2019, then fell by 20.1% to $50959.0 in 2020.
  • Its last three reported values are $50959.0 in Q2 2020, $63775.0 for Q1 2020, and $63776.0 during Q4 2019.